


**Partnership with Sysmex**  
**on functional optimization techniques for CAR-T cells**

Noile-Immune Biotech, Inc. headquartered in Minato-ku (“Noile”) and Sysmex Corporation headquartered in Kobe (“Sysmex”) have signed a joint research agreement for the next-generation cell therapies on July 27, 2023. The next-generation cell therapies will be developed by a combination of the CAR-T cell functional optimization technology from Sysmex and PRIME (Proliferation-Inducing and Migration-Enhancing) CAR-T technology from Noile.

### Collaboration Diagram



By combining the two companies' technologies, it is expected to enhance the function of PRIME CAR-T cells and to build CAR-T cell therapies with greater efficacy against solid cancers.

Under this partnership, Noile and Sysmex will conduct joint research and also aim to commercialize the results of our research. Any further details of the agreement are not disclosed. The impact of this

agreement on our business results is immaterial.

#### About Sysmex

Sysmex defines Sysmex's mission as “Shaping the advancement of healthcare” with “The Sysmex Way”, the Group’s Corporate Philosophy. Established in 1968, Sysmex has striven to contribute to resolving global medical challenges through the core business in laboratory testing of blood, urine, and other specimens, and today Sysmex support the health of people in more than 190 countries and regions around the world. In addition to generating further innovations in the core laboratory testing business, Sysmex will continue to pursue challenges in new fields such as surgical support robots, in order to enhance the “healthcare journey”—the life-long healthcare experience that each individual undergoes—based on the corporate message, “Together for a better healthcare journey.” Sysmex will also strive to deliver new value through our unique technologies and solutions as well as through creative collaborations with a variety of partners. Sysmex is committed to contributing to the delivery of optimal healthcare for each and every individual, in line with the universal human desire to live a long and healthy life.

For more information about Sysmex, please refer to ([www.sysmex.co.jp](http://www.sysmex.co.jp)).

#### About CAR-T cells.

“CAR-T cells” refer to Chimeric antigen receptor T cells, and are T cells transfected with artificial chimeric antigen receptors that combine single-chain antibodies specific to cell-surface antigens in cancer with molecular signaling regions involved in activation of T cells.

#### About PRIME Technology

In addition to enhancing the function of genetically modified immune cells such as CAR-T cells, this technology activates the host's own immune cells. Noile has the exclusive right of PRIME technology.

**Noile-Immune Biotech, Inc., established as a university start-up, aims to contribute to the arrival of an era when we can overcome cancer through next-generation cancer immunotherapies, centering on PRIME technology.**

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech, Inc.

Department of Administration

E-mail: [ir@noile-immune.com](mailto:ir@noile-immune.com)